CD33 and acute myeloid leukemia: Bispecific CD33-targeting antibodies tested in clinical trials in patients with AML include, among others, the CD33/CD3-specific drugs AG330 and AMG673, the tetravalent CD33/CD3 tandem diabody construct AMV564, and the humanized single-chain bispecific CD33/CD3 antibody GEM333 (Table 3) [135,136,137,138,139].